Maddi Hebebrand, MC, Associate Editor

According to the company, comparative tests revealed PN-881 surpasses or matches the efficacy of current injectable IL-17 therapies.

Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.

The study underscores the need for careful dietary advice to balance effective AD management and minimize food allergy risks.

Research suggested acne is primarily inflammatory, occurring even in unaffected skin, redefining its pathophysiology.

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

The company’s phase 3 trials show JNJ-2113 significantly improves skin clearance and tolerability for patients with moderate to severe psoriasis.

Patients treated with dupilumab saw substantial healing, with over 70% achieving >50% lesion improvement in 24 weeks.

November's cover feature highlights the revolutionary role of artificial intelligence in the development of zasocitinib for the treatment of psoriasis.

A recent analysis found primary closure in HS surgery has higher recurrence rates, while secondary intention healing avoids complications but prolongs recovery.

Delgocitinib is indicated for adults with CHE who either do not respond to or cannot use topical corticosteroids.

The study calls for improved diversity in clinical training materials to help future clinicians better recognize conditions on darker skin.

Murase discussed safe dermatologic treatments during lactation, especially for chronic conditions needing biologics.

Murase identifies 4 main pregnancy dermatoses—atopic eruption, polymorphic eruption, extrahepatic cholestasis, and pemphigoid gestationis—as "baby bumps."

Murase noted small molecule treatments, like JAK inhibitors, remain unsafe for pregnant women.

The study demonstrated significant reductions in inflammatory and non-inflammatory lesions for Hispanic patients using CAB gel.

Chilukuri shared that 2 new sunscreen ingredients, physalis angulata and pycnogenol, can prevent heat-induced pigmentation, offering new options for patients.

Affordable at-home treatments, including microneedling and benzoyl peroxide, were top pearls at Chilukuri's Elevate-Derm session.

Catch up on coverage from the second day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

From diet recommendations to biologic advancements, Jennifer Hsiao, MD, covered essential updates for treating patients with HS.

In a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.

APPs found that patients on systemic therapies for AD experience fewer issues with adherence compared to those using topicals only.

Catch up on coverage from the first day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Mark Gimbel, MD, and Whitney High, MD, presented complex cases that underscore the critical need for comprehensive approaches in diagnosing melanocytic lesions.

Cheever shared with Dermatology Times her excitement for educational opportunities, networking, and presentations from experts in the specialty.

Share with us the topics you want to learn more about at Elevate-Derm West.

Researchers noted that ethical use of AR and VR in cosmetic care requires balancing technological benefits with patient safety and privacy.

Researchers stated the dual-action therapy could offer a promising approach to treat progressive non-segmental vitiligo.

Click here to test your knowledge and read more about the treatment landscape of chronic hand eczema.

After 1year of dupilumab treatment, researchers reported 76.5% of patients achieved CR, with further improvement to 85.6% after 3 years.

Motivators like health benefits, altruism, and trust in clinicians enhance participant retention and adherence in melanoma research, according to MEL-SELF findings.